This wiki has undergone a migration to Confluence found Here
Difference between revisions of "2017-11-08 SGB Conference Call"
Jump to navigation
Jump to search
(→Agenda) |
|||
Line 78: | Line 78: | ||
*Approve Minutes of [[2017-10-25_SGB_Conference_Call]] | *Approve Minutes of [[2017-10-25_SGB_Conference_Call]] | ||
*Action Items | *Action Items | ||
+ | **Review GOM with respect to where SGB and precepts should be reflected | ||
+ | **Recommend to TSC to work with CTO on architecture and tooling strategy to support the work of the committees in following the precepts | ||
+ | **Ask Vocab to approve a motion that it was the WG’s intention in R3 for the Expansion profile to be balloted as STU. If PA has not documented approval, send them the same message | ||
+ | **Paul to verify with Karen that the documentation on the FHIR R3 ballot STU approvals is sufficient | ||
*Discussion Topics | *Discussion Topics | ||
+ | **Finish review of mixed ballot content precept | ||
+ | **Precept implementation strategy | ||
+ | **Backwards compatibility consistency and definition across families | ||
+ | *[http://wiki.hl7.org/index.php?title=List_of_Precepts_Under_Development Precepts to Develop] | ||
*Parking Lot | *Parking Lot | ||
+ | **Review Publishing M&C updates regarding dual roles | ||
+ | **How do we deal with making sure that WGs involve those whose content domain they’re touching? (CIMI and Pharmacy and Lab models) | ||
+ | **Review Mission and Charter | ||
+ | **Handling situations where two documents come out of one project | ||
+ | **[http://wiki.hl7.org/index.php?title=FHIR_Product_Director_Page FHIR Product Director Position Description]: we should 1) review further and draft feedback, then 2) map back the description to the role of FGB | ||
+ | **Drafting Shared Product Management Responsibilities | ||
+ | **Levels of standards | ||
+ | **Separation of concerns | ||
+ | **Ownership of content | ||
+ | **ISM | ||
+ | **Ask methodology groups to define how the definition of substantive change applies to their product family; management groups must then operationalize | ||
===Minutes=== | ===Minutes=== |
Revision as of 22:17, 6 November 2017
back to Standards Governance Board main page
HL7 SGB Minutes |
Date: 2017-11-08 Time: 10:00 AM Eastern | ||
Facilitator | Paul/Calvin | Note taker(s) | Anne |
Attendee | Name
| ||
Calvin Beebe | |||
Lorraine Constable | |||
Russ Hamm | |||
Tony Julian | |||
Paul Knapp | |||
Austin Kreisler | |||
Wayne Kubick | |||
Thom Kuhn | |||
Ken McCaslin | |||
Rik Smithies | |||
Sandy Stuart | |||
Quorum: Chair + 4 |
Agenda
- Agenda review
- Approve Minutes of 2017-10-25_SGB_Conference_Call
- Action Items
- Review GOM with respect to where SGB and precepts should be reflected
- Recommend to TSC to work with CTO on architecture and tooling strategy to support the work of the committees in following the precepts
- Ask Vocab to approve a motion that it was the WG’s intention in R3 for the Expansion profile to be balloted as STU. If PA has not documented approval, send them the same message
- Paul to verify with Karen that the documentation on the FHIR R3 ballot STU approvals is sufficient
- Discussion Topics
- Finish review of mixed ballot content precept
- Precept implementation strategy
- Backwards compatibility consistency and definition across families
- Precepts to Develop
- Parking Lot
- Review Publishing M&C updates regarding dual roles
- How do we deal with making sure that WGs involve those whose content domain they’re touching? (CIMI and Pharmacy and Lab models)
- Review Mission and Charter
- Handling situations where two documents come out of one project
- FHIR Product Director Position Description: we should 1) review further and draft feedback, then 2) map back the description to the role of FGB
- Drafting Shared Product Management Responsibilities
- Levels of standards
- Separation of concerns
- Ownership of content
- ISM
- Ask methodology groups to define how the definition of substantive change applies to their product family; management groups must then operationalize
Minutes
Meeting Outcomes
Actions
|
Next Meeting/Preliminary Agenda Items |
© 2017 Health Level Seven® International. All rights reserved